Metraipolis › archive › dc_a48c558f61eb
Evaluating the impact of leniolisib treatment on symptoms and health-related quality of life in activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome — Europe PMC PMID:42183294
- Source
- Europe PMC (en)
- Original
- https://europepmc.org/article/MED/42183294
- DOI
- 10.3389/fimmu.2026.1739437
- License (as archived)
- solo-consultazione
- Archived
- 2026-10-09T23:19:46.072Z
- SHA-256 of the archived text
01556c0678a639bea418c15cc06efd283355d43cfabb08bdaa8d0cbe4f440b53- Stable URL of this page
https://metraipolis.com/documento/dc_a48c558f61eb
How to cite
Evaluating the impact of leniolisib treatment on symptoms and health-related quality of life in activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome — Europe PMC PMID:42183294 — Europe PMC (en), https://europepmc.org/article/MED/42183294 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_a48c558f61eb (Metraipolis archive dc_a48c558f61eb, sha256 01556c0678a639bea418c15cc06efd283355d43cfabb08bdaa8d0cbe4f440b53)
BibTeX
@misc{dca48c558f61eb,
title = {Evaluating the impact of leniolisib treatment on symptoms and health-related quality of life in activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome — Europe PMC PMID:42183294},
howpublished = {Europe PMC (en)},
url = {https://europepmc.org/article/MED/42183294},
note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_a48c558f61eb; sha256 01556c0678a639bea418c15cc06efd283355d43cfabb08bdaa8d0cbe4f440b53},
year = {2026}
}Archived text
The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/42183294. Agents can read the archived copy with the MCP tool read_document.